The role of DPYD and the effects of DPYD suppressor luteolin combined with 5-FU in pancreatic cancer.

Hiroyuki KatoMotonori SatoAya Naiki-ItoShingo InagumaMakoto SanoMasayuki KomuraYuko NagayasuKuang XiaochenAkihisa KatoYoichi MatsuoHideaki IjichiSatoru Takahashi

Published in: Cancer medicine (2024)

We have elucidated that DPYD expression contributes to proliferation, invasiveness, and 5-FU resistance, in PDACs. The combination therapy of Lut and 5-FU holds the potential for enhanced efficacy against PDACs.

Keyphrases

combination therapy
poor prognosis
signaling pathway
human health
binding protein
climate change
risk assessment
long non coding rna